mProX™ Human GALR2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human GALR2 Stable Cell Line (S01YF-0923-PY72). Click the button above to contact us or submit your feedback about this product.
Laura (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Kathleen (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Galanin decreases mitochondrial ROS production via GalR2.
Displayed are illustrative visuals and quantification of MitoSox Red labeling within H9C2 cells following transfection with either control siRNA (siControl) or GalR2 siRNA (siGalR2) during the imposition of isoproterenol-induced stress (ISO). The data reflects the mean ± SEM derived from three distinct experiments. Significance levels: *p < 0.05 compared to the control; #p < 0.05 compared to ISO.
Ref: Boal, Frederic, et al. "Galanin regulates myocardial mitochondrial ROS homeostasis and hypertrophic remodeling through GalR2." Frontiers in Pharmacology 13 (2022): 869179.
Pubmed: 35431947
DOI: 10.3389/fphar.2022.869179
Research Highlights
Cha JJ, et al. "Spexin-based galanin receptor 2 agonist improves renal injury in mice with type 2 ." Animal cells and systems, 2023.
An analysis was conducted on the effects of NS200 administration in non-diabetic db/m control, db/db mice, and NS200-treated db/db mice. Results showed that NS200 had no significant impact on body weight, food and water intake, urinary volume, fasting blood glucose level, or HbA1c levels in db/db mice. Additionally, NS200 treatment did not affect insulin and glucose tolerance. However, NS200 did improve urinary albumin excretion and glomerulosclerosis in diabetic kidneys. The use of NS200 also resulted in the inhibition of TGFbeta1 and insulin signaling pathways, including PI3 K/AKT/ERK. These findings suggest that a spexin-based GALR2 agonist can potentially be used as a treatment for diabetic nephropathy by reducing renal fibrosis in type 2 diabetes mice.
Pubmed:
37789932
DOI:
10.1080/19768354.2023.2263067
Gallagher DM, et al. "An update on galanin and spexin and their potential for the treatment of type 2 ." Peptides, 2023.
In recent studies, Spexin (SPX) and galanin (GAL) have been identified as neuropeptides that are widely expressed in the central nervous system and peripheral tissues in various species, including humans. These peptides exert their biological actions by binding and activating the galanin receptors (GALR), specifically GALR1, GALR2 and GLAR3. While GAL activates all three receptors, SPX binds more selectively to GALR2 and GLAR3. GAL has been extensively studied and its role in energy homeostasis is well-established, while research on the physiological effects of SPX is still in its early stages. However, it is known that both peptides play a crucial role in regulating energy balance, making them potential targets for therapeutic interventions in metabolic disorders such as obesity and type 2 diabetes. Although both peptides activate GALRs, GAL may be more effective in treating eating disorders such as anorexia and bulimia, while SPX may have potential therapeutic applications for obesity and obesity-related diabetes. This brief review aims to provide an updated overview of the biology of SPX and GAL, and the potential use of these peptides for the treatment of metabolic disorders.
Pubmed:
37714335
DOI:
10.1016/j.peptides.2023.171096
